<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixty-two patients with high-risk <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> were treated with the FLAD regimen [3 days of treatment with fludarabine 30 mg/m(2), <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (AraC) 2 g/m(2), and liposomal <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> 80 mg/m(2)] </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients were either refractory to standard induction regimens (8), were in first or second relapse (13), or received therapy as first-line treatment [21 patients, 16 were above 60 years of age and 5 had post-<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>] </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) patients were treated for relapsed (7) or refractory disease (10) </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients had <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in the <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>FLAD was well tolerated by most patients </plain></SENT>
<SENT sid="5" pm="."><plain>Ten major infectious complications were recorded while no signs of cardiac toxicity were observed </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients (8%) died before day 28 with <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypocellular marrow</z:e>, mainly of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> or <z:mp ids='MP_0001914'>hemorrhage</z:mp>, and response could not be evaluated </plain></SENT>
<SENT sid="7" pm="."><plain>Complete response rate was 62% and 69% among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients treated at diagnosis or for <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">relapsed disease</z:e>, respectively, and 59% among the ALL patients </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, FLAD managed to overcome the negative impact of poor prognosis karyotype in ALL patients, since five of the seven patients with t(9;22) or complex karyotype achieved complete remission (CR) </plain></SENT>
<SENT sid="9" pm="."><plain>Nine patients underwent bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="10" pm="."><plain>Among the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients who were treated at diagnosis or for relapse, the median duration of CR was 7 months (range: 2-18) and 8 months (range: 2-26), respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Median survival among these patients was 8 (range: 1-40) and 12 (range: 1-30) months, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>Similar values were found in ALL patients </plain></SENT>
<SENT sid="13" pm="."><plain>In conclusion, FLAD may be an effective alternative treatment for patients with relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and for patients with ALL who failed first-line therapy </plain></SENT>
</text></document>